Labcorp Holdings (FRA:N6B) Cyclically Adjusted Revenue per Share: €0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:N6B Labcorp Holdings Inc FRA:N6B
80 GF Score
Price €266.00
GF Value €234.36
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is Labcorp Holdings Cyclically Adjusted Revenue per Share?

Labcorp Holdings FRA:N6B -2.92% 80 Cyclically Adjusted Revenue per Share is €0.00 as of Jun. 2026. GuruFocus rates FRA:N6B with a GF Score™ of 80/100 and a GF Value™ of €234.36 (Modestly Overvalued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Labcorp Holdings's adjusted revenue per share for the three months ended in Jun. 2026 was €39.495. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.00 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Labcorp Holdings's average Cyclically Adjusted Revenue Growth Rate was 6.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 7.20% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 9.50% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 11.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Labcorp Holdings was 12.80% per year. The lowest was -2.30% per year. And the median was 9.25% per year.

As of today (2026-07-31), Labcorp Holdings's current stock price is €266.00. Labcorp Holdings's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was €0.00. Labcorp Holdings's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Labcorp Holdings was 2.52. The lowest was 1.08. And the median was 1.78.


Labcorp Holdings  (FRA:N6B) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Labcorp Holdings was 2.52. The lowest was 1.08. And the median was 1.78.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Labcorp Holdings Cyclically Adjusted Revenue per Share Related Terms


Labcorp Holdings Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Labcorp Holdings's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Labcorp Holdings Cyclically Adjusted Revenue per Share Chart

Labcorp Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 94.16 114.25 118.58 135.12 127.53

Labcorp Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 125.06 125.48 127.53 132.36 0.00

FRA:N6B vs DGX, MTD, GH: Cyclically Adjusted Revenue per Share Comparison

For the Diagnostics & Research subindustry, Labcorp Holdings's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Labcorp Holdings Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Labcorp Holdings's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Labcorp Holdings's Cyclically Adjusted PS Ratio falls into.


FRA:N6B
80GF Score
Labcorp Holdings Inc FRA:N6B
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Labcorp Holdings Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Labcorp Holdings's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=39.495/333.9520*333.9520
=39.495

Current CPI (Jun. 2026) = 333.9520.

Labcorp Holdings Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 20.510 241.428 28.370
201612 21.203 241.432 29.328
201703 21.638 243.801 29.639
201706 21.698 244.955 29.581
201709 21.209 246.819 28.696
201712 22.322 246.524 30.238
201803 22.340 249.554 29.895
201806 23.821 251.989 31.569
201809 23.626 252.439 31.255
201812 24.236 251.233 32.216
201903 24.826 254.202 32.615
201906 25.813 256.143 33.654
201909 27.051 256.759 35.184
201912 27.123 256.974 35.248
202003 26.292 258.115 34.017
202006 25.166 257.797 32.600
202009 33.719 260.280 43.263
202012 37.544 260.474 48.135
202103 35.489 264.877 44.744
202106 32.462 271.696 39.900
202109 35.563 274.310 43.295
202112 9.845 278.802 11.792
202203 37.668 287.504 43.753
202206 29.842 296.311 33.633
202209 31.924 296.808 35.919
202212 31.005 296.797 34.886
202303 31.880 301.836 35.272
202306 31.462 305.109 34.436
202309 32.922 307.789 35.720
202312 32.533 306.746 35.418
202403 34.504 312.332 36.892
202406 35.495 314.175 37.729
202409 35.037 315.301 37.110
202412 37.807 315.605 40.005
202503 36.705 319.799 38.329
202506 36.450 322.561 37.737
202509 36.274 324.800 37.296
202512 36.088 324.054 37.190
202603 36.912 330.213 37.330
202606 39.495 333.952 39.495

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €0.00 mean?
Labcorp Holdings (FRA:N6B) has a Cyclically Adjusted Revenue per Share of €0.00 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Labcorp Holdings and its competitors.
Is Labcorp Holdings' Cyclically Adjusted Revenue per Share too high?
Labcorp Holdings' current Cyclically Adjusted Revenue per Share is €0.00. Overall, Labcorp Holdings has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Labcorp Holdings' Cyclically Adjusted Revenue per Share compare to DGX and MTD?
Labcorp Holdings' Cyclically Adjusted Revenue per Share of €0.00 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Labcorp Holdings and its competitors. Labcorp Holdings's current Cyclically Adjusted Revenue per Share is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labcorp Holdings stock overvalued right now?
Based on GuruFocus' analysis, Labcorp Holdings (FRA:N6B) is currently considered Modestly Overvalued. The stock's GF Value™ is €234.36, compared to a current price of €266.00 — trading 13.5% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €0.00. Labcorp Holdings' overall GF Score™ is 80/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Labcorp Holdings (FRA:N6B), the current Cyclically Adjusted Revenue per Share is €0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Labcorp Holdings (FRA:N6B) Overvalued in 2026?

Based on GuruFocus' analysis, Labcorp Holdings stock appears to be overvalued. The current stock price of €266.00 is trading 13.5% above its estimated GF Value™ of €234.36. GuruFocus considers Labcorp Holdings to be Modestly Overvalued.

Key valuation signals for FRA:N6B:

  • Cyclically Adjusted Revenue per Share: €0.00
  • GF Value™: €234.36 vs. price of €266.00 (13.5% above fair value)
  • GF Score™: 80/100 with 8 warning signs

No single metric tells the full story. See the FRA:N6B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Labcorp Holdings Business Description

Other Exchanges LH:USA0JSY:UKN6B:Germany
Address 358 South Main Street, Burlington, NC, USA, 27215
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from uncomplicated routine blood and urine screens to complex oncology and genomic testing.
80GF Score

Get the complete analysis for FRA:N6B

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€266.00
Price
€234.36
GF Value